GAIN THERAPEUTICS INC. - COMMON STOCK

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

01 May 2025 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

30 Apr 2025 07:45:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

10 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

28 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

27 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

14 Mar 2025 07:45:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

06 Mar 2025 07:55:00 By Nasdaq GlobeNewswire

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

06 Feb 2025 08:45:00 By Nasdaq GlobeNewswire

Gain Therapeutics To Participate in Upcoming Investor Conferences

05 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

08 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

07 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

23 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics To Present At Biotech Showcase 2025

11 Dec 2024 08:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

14 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

23 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

09 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

07 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at Upcoming Investor Conferences

03 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire